Sept 10 (Reuters) - Private equity firm GTCR has struck

a 4.1 billion euro ($4.8 billion) deal to buy Czech generic

drugmaker Zentiva from Advent International, the

Financial Times reported on Wednesday, citing unidentified

sources.

Reuters could not immediately confirm the report. GTCR,

Advent and Zentiva did not immediately respond to a Reuters

request for comment.

The deal has been finalized and is expected to be announced

within days, the newspaper said.

Boston-based Advent bought Zentiva, which makes a wide range

of generic and over-the-counter drugs, from French

pharmaceutical giant Sanofi for 1.9 billion euros in

2018.

Zentiva operates in over 30 countries and employs more than

5,000 people, according to the company's website.

India's Economic Times newspaper reported last month that

Aurobindo Pharma was leading the race to buy Zentiva

for up to $5.5 billion.

($1 = 0.8548 euros)

(Reporting by Gnaneshwar Rajan in Bengaluru; Editing by Sonia

Cheema and Mrigank Dhaniwala)